Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)

NCT ID: NCT04486846

Last Updated: 2021-06-10

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-30
• Study Completion Date: 2022-03-31

Brief Summary

The purpose of this single institution pilot study is to determine the feasibility of implementing an eHealth prostate cancer surveillance program through the eVisit electronic medical record patient portal. The investigators will assess patient compliance and satisfaction with eVisit follow up care in lieu of in person clinic visits.

Detailed Description

Telehealth offers the opportunity to transform cancer surveillance into a patient-centered effort with shared leadership between patient and oncologist. Peer-to-peer electronic communications can improve the collaboration between oncologist and primary care provider (PCP) as patients transition back to primary care as their primary health provider. The investigators propose to test a patient-centered eHealth surveillance program utilizing novel asynchronous telehealth tools to provide patient-reported outcome symptom monitoring using the electronic medical record's patient portal (eVisit).

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

eVisit

The study intervention will be an electronically performed surveillance program replacing face-to-face clinic follow-up visits. At 3 month intervals for 1 year, the patient will receive an email reminder generated by the patient portal to complete lab testing and eVisit questionnaire.

Group Type: EXPERIMENTAL

eVisit

Intervention Type: OTHER

electronic surveillance program in lieu of in-person clinic visit

Interventions

eVisit

electronic surveillance program in lieu of in-person clinic visit

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• ≥ 18 years old with histologically confirmed prostate cancer
• Completed curative intent treatment to the prostate +/- pelvis
• Deemed to be "without evidence of active disease" by treating provider with at least 1 follow up visit 3 or more months after treatment completion
• MyChart account or willingness to open account
• Access to the internet

Exclusion Criteria

• Documented extrapelvic metastases
• PSA meeting definition of recurrence (>0.2 ng/ml for prostatectomy patients or nadir + 2 ng/ml for radiation patients) and rising with doubling time less than 1 year

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Duke University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bridget Koontz, MD

Role: PRINCIPAL_INVESTIGATOR

Duke Health

Locations

Duke Cancer Institute Cary

Cary, North Carolina, United States

Durham Regional Hospital

Durham, North Carolina, United States

Duke University Medical Center

Durham, North Carolina, United States

Duke Raleigh Hospital

Raleigh, North Carolina, United States

Countries

United States

Other Identifiers

Pro00104751

Identifier Type: -

Identifier Source: org_study_id